Karolinska Development AB's Portfolio Company Modus Recruits New Chief Medical Officer
STOCKHOLM - 14 September 2017. Karolinska Development's portfolio company Modus Therapeutics AB, which's drug candidate sevuparin is currently in a phase II study for treatment of patients with sickle cell disease, has recruited Professor Thomas Knittel as its new Chief Medical Officer (CMO).
Thomas Knittel (b. 1962), M.D., Ph.D. from University of Mainz with a speciality in internal medicine and medical gastroenterology and MBA from Kellogg School of Management/WHU, has more than 10 years of clinical experience from internal medicine and over 15 years of experience from research and development, medical affairs and marketing within the pharmaceutical industry.
Thomas Knittel formally took up his appointment at Modus Therapeutics in mid-August2017.
Further information and comments from Modus Therapeutics' CEO Ellen K Donnelly and Thomas Knittel are available at the link below: http://www.modustx.com/media/press-release/?y=2017
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: email@example.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.